TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34403648

Group type: EXPERIMENTAL
Intervention: MgSO4 (60 mg.kg‐1) with rocuronium 0.3 mg.kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MgSO4 (60 mg.kg‐1) with rocuronium 0.6 mg.kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MgSO4 (60 mg.kg‐1) with rocuronium 1.2 mg.kg‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (saline) with rocuronium 0.3 mg.kg‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (saline) with rocuronium 0.6 mg.kg‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (saline) with rocuronium 1.2 mg.kg‐1
Number of subjects: 180
Study: 32981192

Group type: EXPERIMENTAL
Intervention: Days with clinical hypoglycemia (54-69 mg/dL)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Days with clinically serious hypoglycemia (<54 mg/dL)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Days without hypoglycemia
Number of subjects: 122
Study: 33749317

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 34759049

Group type: EXPERIMENTAL
Intervention: Hearing aid use for six months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 32
Study: 35710444

Group type: EXPERIMENTAL
Intervention: Doxycycline post-exposure prophylaxis (dPEP)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Standard of care (STI screening and treatment and risk-reduction counseling without dPEP)
Number of subjects: 446
Study: 33275326

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone and bupropion (NB)
Number of subjects: 2073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2073
Study: 35156933

Group type: COMPARATOR
Intervention: Misinformation only
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Misinformation + correction
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Misinformation + correction + rebuke
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Misinformation + correction + rebuke + second correction
Number of subjects: 500
Study: 35911215

Group type: EXPERIMENTAL
Intervention: Virtual reality serious game training program, twice a day for at least 10 days during hospitalization
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard psychiatric care
Number of subjects: 64
Study: 35156252

Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Body exposure intervention
Number of subjects: 30
Study: 33239197

Group type: EXPERIMENTAL
Intervention: Bipolar Loop
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 40
Study: 33838565

Group type: EXPERIMENTAL
Intervention: Daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 783

Group type: COMPARATOR
Intervention: Daily oral dose of 1 tablet containing 10 mg enalapril only
Number of subjects: 783
Study: 32978984

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (participants received a text message after blood product dispatch).
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Control group (no text message intervention).
Number of subjects: 2540
Study: 34273681

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (CEx; n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo supplementation (LEx; n=7)
Number of subjects: 14
Study: 33054780

Group type: EXPERIMENTAL
Intervention: Flexible intramedullary rod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intramedullary rod
Number of subjects: 0
Study: 36377398

Group type: EXPERIMENTAL
Intervention: One-year lifestyle weight loss intervention (IG)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 94
Study: 34801745

Group type: EXPERIMENTAL
Intervention: iTRAQ 2D LC‐MS/MS method in the training group (12 adults)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PRM analysis in the testing group (28 adults)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study: 33115319

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study: 33878774

Group type: EXPERIMENTAL
Intervention: Standardized video education
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (no video education)
Number of subjects: 210
Study: 32893155

Group type: EXPERIMENTAL
Intervention: Immersive virtual patient simulation (IVPS) training combined with regular faculty courses
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (regular courses alone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Satisfaction scores from the IVPS group
Number of subjects: 85
Study: 35687479

Group type: EXPERIMENTAL
Intervention: Active Videogame Training (VR training)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional neurodevelopmental-based physiotherapy
Number of subjects: 23
Study: 34185386

Group type: EXPERIMENTAL
Intervention: Neural therapy (NT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (hand rest and thumb spica splint)
Number of subjects: 36
Study: 32223554

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (PG)
Number of subjects: 66
Study: 35875898

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Osteopathic Medicine (OM)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no study intervention)
Number of subjects: 121
Study: 34006898

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NCT) with adriamycin and cyclophosphamide followed by docetaxel
Number of subjects: 123

Group type: COMPARATOR
Intervention: Neoadjuvant endocrine therapy (NET) with goserelin and tamoxifen
Number of subjects: 123
Study: 32858524

Group type: EXPERIMENTAL
Intervention: Evidence-based educational brochure and access to local fitness facilities (PAG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 33201779

Group type: EXPERIMENTAL
Intervention: NZBC extract (600 mg/day for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NZBC extract
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 32059692

Group type: COMPARATOR
Intervention: Metformin 850 mg PO bid
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg PO bid plus dapagliflozin 10 mg PO qd
Number of subjects: 108
Study: 35691087

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 518
Study: 33835174

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 6 mg orally 30 minutes before chemotherapy initiation on day 1)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 12 mg orally 30 minutes before chemotherapy initiation on day 1)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 36454579

Group type: EXPERIMENTAL
Intervention: Caffeine-based energy drink consumed before exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine-based energy drink
Number of subjects: 0
Study: 32951084

Group type: EXPERIMENTAL
Intervention: Trastuzumab + lapatinib
Number of subjects: 430

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 430
Study: 32959761

Group type: EXPERIMENTAL
Intervention: Chlorhexidine hand cleansing promotion
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard practices (control)
Number of subjects: 258
Study: 35091170

Group type: EXPERIMENTAL
Intervention: Insomnia with objective short sleep duration (ISSD)
Number of subjects: 128
Study: 34902089

Group type: EXPERIMENTAL
Intervention: 25% albumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 60
Study: 34476568

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg twice a day for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33884978

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-dose atorvastatin (20 mg)
Number of subjects: 100
Study: 36052527

Group type: EXPERIMENTAL
Intervention: 60 days of head-down bed rest (HDBR) with daily multivitamin supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60 days of head-down bed rest (HDBR)
Number of subjects: 20
Study: 32039461

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (radiation therapy) for early endometrial cancer
Number of subjects: 419
Study: 34897366

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg once daily
Number of subjects: 2574

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg plus MTX
Number of subjects: 2574

Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every other week plus MTX
Number of subjects: 2574
Study: 32197633

Group type: EXPERIMENTAL
Intervention: Family caregivers
Number of subjects: 3444

Group type: COMPARATOR
Intervention: Non-caregivers
Number of subjects: 3444

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3444
Study: 34016037

Group type: EXPERIMENTAL
Intervention: Anabolic steroid (Nandrolone Decanoate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (Placebo - Saline)
Number of subjects: 23
Study: 33425079

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) + treatment as usual (TAU)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 52
Study: 36522805

Group type: EXPERIMENTAL
Intervention: 3 g/d pure EPA (ethyl ester, ≥97% purity) for 10 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 g/d pure DHA (ethyl ester, ≥97% purity) for 10 weeks
Number of subjects: 21
Study: 34409753

Group type: EXPERIMENTAL
Intervention: 6-week exercise training program, three times a week
Number of subjects: 0
Study: 32138995

Group type: EXPERIMENTAL
Intervention: PowerSoil kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: UNEX method
Number of subjects: 0
Study: 35030335

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (360 mg nivolumab intravenously every 3 weeks plus oxaliplatin-based chemotherapy)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (placebo plus oxaliplatin-based chemotherapy)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 724
Study: 33927004

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 1515
Study: 33276274

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control condition (WLC)
Number of subjects: 100
Study: 32074794

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenic hilar lymph node dissection
Number of subjects: 222

Group type: COMPARATOR
Intervention: Open splenic hilar lymph node dissection
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: No. 4s lymph node examination
Number of subjects: 222
Study: 35921605

Group type: EXPERIMENTAL
Intervention: LEN-TACE (Lenvatinib plus on-demand TACE)
Number of subjects: 338

Group type: COMPARATOR
Intervention: LEN (Lenvatinib monotherapy)
Number of subjects: 338
Study: 33413636

Group type: EXPERIMENTAL
Intervention: BM‐MSC group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 33327300

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 0
Study: 34120160

Group type: EXPERIMENTAL
Intervention: S-methyl-L-thiocitrulline (SMTC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34227468

Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 0
Study: 35445439

Group type: EXPERIMENTAL
Intervention: 5-HT2 antagonist cyproheptadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33610330

Group type: EXPERIMENTAL
Intervention: Angled screw-channel abutments
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Straight abutments
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cement-retained restorations
Number of subjects: 200
Study: 34569710

Group type: EXPERIMENTAL
Intervention: Provider-delivered testing (option 1)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: HIV self-testing on site in a private booth (option 2)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Provision of a test kit to test off site (option 3)
Number of subjects: 951
Study: 36434008

Group type: EXPERIMENTAL
Intervention: Frequency Specific Cognitive Training (FSCT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo training (pFSCT)
Number of subjects: 46
Study: 34220576

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (DBD-PCB)
Number of subjects: 36
Study: 35525837

Group type: EXPERIMENTAL
Intervention: SacralStim system (SNM on)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (SNM off)
Number of subjects: 0
Study: 33516141

Group type: EXPERIMENTAL
Intervention: Oral hydration (500 mL of water two hours before and 2000 mL during the 24 h after CE-CT)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Intravenous hydration (sodium bicarbonate 166 mmol/L 3 mL/kg/h starting one hour before and 1 mL/kg/h during the first hour after CE-CT)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous hydration
Number of subjects: 264
Study: 33076981

Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observations (NBO) system
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2566
Study: 33420905

Group type: EXPERIMENTAL
Intervention: Social support and self-efficacy
Number of subjects: 781

Group type: COMPARATOR
Intervention: Low social support
Number of subjects: 781

Group type: COMPARATOR
Intervention: Comorbidities and cGVHD
Number of subjects: 781

Group type: COMPARATOR
Intervention: Healthcare adherence
Number of subjects: 781
Study: 32419245

Group type: EXPERIMENTAL
Intervention: Gaussian process regression (GPR)
Number of subjects: 4231

Group type: EXPERIMENTAL
Intervention: Shallow neural network (SNN)
Number of subjects: 4231

Group type: COMPARATOR
Intervention: Empirical model (EM)
Number of subjects: 4231
Study: 35443742

Group type: EXPERIMENTAL
Intervention: VEN + AZA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VEN + LDAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZA + PBO
Number of subjects: 0

Group type: COMPARATOR
Intervention: LDAC + PBO
Number of subjects: 0
Study: 33999729

Group type: EXPERIMENTAL
Intervention: Wellness coaching for smoking cessation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 31
Study: 33418379

Group type: EXPERIMENTAL
Intervention: Maudsley 3-item Visual Analogue Scale (M3VAS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Factor analysis of M3VAS
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Internal consistency of M3VAS
Number of subjects: 180
Study: 35608693

Group type: EXPERIMENTAL
Intervention: Medial posterior tibial slope (MPTS) in ACL tear group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lateral posterior tibial slope (LPTS) in ACL tear group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Posterior tibial slope (PTS) in ACL tear group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medial tibial plateau depth (MTPD) in ACL tear group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROC analysis for MPTS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROC analysis for LPTS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROC analysis for PTS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROC analysis for MTPD
Number of subjects: 60
Study: 33835842

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (T)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy (T + C)
Number of subjects: 231
Study: 36455006

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (thrice weekly)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 105
Study: 34214136

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 6756

Group type: EXPERIMENTAL
Intervention: Neutral information or nudging in favor of screening
Number of subjects: 6756

Group type: EXPERIMENTAL
Intervention: Exclusion from decision-making or nudging against screening
Number of subjects: 6756

Group type: COMPARATOR
Intervention: Control scenarios (no patient involvement)
Number of subjects: 6756
Study: 32660953

Group type: EXPERIMENTAL
Intervention: Novel education intervention (online training video on WenJuanXing platform)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard of care training programme (control arm)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Questionnaire survey (secondary outcome)
Number of subjects: 144
Study: 36055919

Group type: EXPERIMENTAL
Intervention: Ipilimumab and Nivolumab (dual immunotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study: 33647189

Group type: EXPERIMENTAL
Intervention: Combination therapy of ezetimibe/rosuvastatin 10/20 mg
Number of subjects: 36
Study: 34844069

Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine treatment only (Control Group)
Number of subjects: 64
Study: 32623650

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 50

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 50
Study: 33308471

Group type: EXPERIMENTAL
Intervention: UCART19 (1.1-2.3 x 10^6 cells/kg for children; 6 x 10^6 cells, 6-8 x 10^7 cells, or 1.8-2.4 x 10^8 cells for adults)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: UCART19
Number of subjects: 21

Group type: COMPARATOR
Intervention: UCART19 (without alemtuzumab)
Number of subjects: 21
Study: 34818184

Group type: EXPERIMENTAL
Intervention: FGS (Fluorescence Image-Guided Surgery)
Number of subjects: 41

Group type: COMPARATOR
Intervention: WLS (White Light Image-Guided Surgery)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FGS
Number of subjects: 41

Group type: COMPARATOR
Intervention: WLS
Number of subjects: 41
Study: 32554072

Group type: EXPERIMENTAL
Intervention: LIFU-mediated gene delivery to downregulate P2X3 receptor in carotid body (n=14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: LIFU treatment alone (n=4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cationic microbubbles injection alone (n=4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Negative control group (n=10)
Number of subjects: 32
Study: 35711070

Group type: EXPERIMENTAL
Intervention: VGG16-Tilt model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VGG16-Rotation model
Number of subjects: 30
Study: 34070014

Group type: EXPERIMENTAL
Intervention: 20 g whey protein gel (78 mL/368 kJ) consumed for four days
Number of subjects: 24
Study: 32833606

Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 36163034

Group type: EXPERIMENTAL
Intervention: SCRIPT intervention (CRC PRS, tailored risk-specific screening recommendations, and a risk report)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control (standard cancer risk reduction information)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: SCRIPT intervention
Number of subjects: 274
Study: 33429441

Group type: EXPERIMENTAL
Intervention: ENDOANGEL
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1050
Study: 32285449

Group type: EXPERIMENTAL
Intervention: Brief intervention for reducing adolescent substance use (2 sessions for adolescents, 1 session for caregivers)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-intervention interviews
Number of subjects: 30
Study: 36191860

Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IMT
Number of subjects: 88

Group type: COMPARATOR
Intervention: RMTsham
Number of subjects: 88

Group type: COMPARATOR
Intervention: IMTsham
Number of subjects: 88
Study: 34454496

Group type: EXPERIMENTAL
Intervention: Industry partner owned all data
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Publication constraints described
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Industry partner could review data during the trial
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Industry partner could stop the trial early without any specific reason
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Unclear ownership of data
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Unclear if industry partner could review data
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Publication constraints not communicated to trial participants
Number of subjects: 42
Study: 33734131

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with rituximab
Number of subjects: 78

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intracerebral mass (ICM) positivity
Number of subjects: 78

Group type: COMPARATOR
Intervention: >4 organs involved at diagnosis
Number of subjects: 78
Study: 36134382

Group type: EXPERIMENTAL
Intervention: Medical Safety Huddles
Number of subjects: 0
Study: 33250404

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: RAKI (developed)
Number of subjects: 382